secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001193125-26-085399
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy
--------------------------------------------------------------------------------

- Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.
- Cash, equivalents and marketable securities $256.0M at Dec 31, 2025; runway through at least 2027.
- Launched 'dabogratinib 3x3' strategy: three pivotal-ready studies in LG-UTUC, IR NMIBC, and ACH.
- SURF302 (IR NMIBC) initial 3-month CR data expected by end 1H 2026; BEACH301 (ACH) interim results 2H 2026.
- Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/0001193125-26-085399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-085399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer